Dr. Gruber is Senior Vice President of Pfizer Vaccine Clinical Research and Development, and is responsible for global clinical development of vaccines. He joined in 1999 as Vice President of Clinical Vaccine Research for Wyeth, now a wholly owned subsidiary of Pfizer. Prior to his position at Wyeth, Dr. Gruber was an Associate Professor of Pediatrics in the Division of Pediatric Infectious Diseases, Vanderbilt University School of Medicine. He also served as the Director of the Diagnostic Virology Laboratory at Vanderbilt University Hospital.

Dr. Gruber is Board Certified in Pediatrics and Pediatric Infectious Diseases.  He is a Fellow of the American Academy of Pediatrics, member of the  Society for Pediatric Research, Fellow of the Infectious Diseases Society of America, and member of the America Society for Microbiology.  Dr. Gruber has served as a consultant reviewer for the National Institutes of Health, NIAID, the Bill and Melinda Gates Foundation, and PATH.  

During his industry career, Dr. Gruber’s clinical research group has been responsible for global clinical development of pneumococcal conjugate, meningococcal conjugate, rLP2086 meningococcal B, Staph aureus, C. difficile, HIV, influenza, RSV, parainfluenza, and HSV vaccines.  Dr Gruber is responsible for guiding clinical research direction for Pfizer’s Group B streptococcus, CMV, and RSV maternal and adolescent vaccine programs.